Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL LARGE VOLUME PARENTERAL MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL XX SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL LARGE VOLUME PARENTERAL MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 INSTALLED BASE DATA
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
16.1 ECONOMIC DEVELOPMENT
17 GLOBAL LARGE VOLUME PARENTERAL MARKET, BY TYPE
17.1 OVERVIEW
17.2 SOFT BAG LVP
17.2.1 BY VOLUME
17.2.1.1. 100 ML-250 ML
17.2.1.2. 250 ML-500 ML
17.2.1.3. 500 ML-1000 ML
17.2.1.4. 1000 ML-2000 ML
17.2.1.5. 2000 ML AND MORE
17.3 PLASTIC BOTTLE LVP
17.3.1 BY VOLUME
17.3.1.1. 100 ML-250 ML
17.3.1.2. 250 ML-500 ML
17.3.1.3. 500 ML-1000 ML
17.3.1.4. 1000 ML-2000 ML
17.3.1.5. 2000 ML AND MORE
17.4 GLASS BOTTLE LVP
17.4.1 BY VOLUME
17.4.1.1. 100 ML-250 ML
17.4.1.2. 250 ML-500 ML
17.4.1.3. 500 ML-1000 ML
17.4.1.4. 1000 ML-2000 ML
17.4.1.5. 2000 ML AND MORE
18 GLOBAL LARGE VOLUME PARENTERAL MARKET, BY ROUTE OF ADMINISTRATION
18.1 OVERVIEW
18.2 INTRAVENOUS
18.3 INTRAPERITONEAL
18.4 SUBCUTANEOUS
18.5 OTHERS
19 GLOBAL LARGE VOLUME PARENTERAL MARKET, BY VOLUME
19.1 OVERVIEW
19.2 100 ML-250 ML
19.3 250 ML-500 ML
19.4 500 ML-1000 ML
19.5 1000 ML-2000 ML
19.6 2000 ML AND MORE
20 GLOBAL LARGE VOLUME PARENTERAL MARKET, BY APPLICATION
20.1 OVERVIEW
20.2 THERAPEUTIC INJECTIONS
20.2.1 100 ML-250 ML
20.2.2 250 ML-500 ML
20.2.3 500 ML-1000 ML
20.2.4 1000 ML-2000 ML
20.2.5 2000 ML AND MORE
20.3 FLUID BALANCE INJECTIONS
20.3.1 100 ML-250 ML
20.3.2 250 ML-500 ML
20.3.3 500 ML-1000 ML
20.3.4 1000 ML-2000 ML
20.3.5 2000 ML AND MORE
20.4 NUTRITIOUS INJECTIONS
20.4.1 100 ML-250 ML
20.4.2 250 ML-500 ML
20.4.3 500 ML-1000 ML
20.4.4 1000 ML-2000 ML
20.4.5 2000 ML AND MORE
20.5 PLASMA SUBSTITUTES
20.5.1 100 ML-250 ML
20.5.2 250 ML-500 ML
20.5.3 500 ML-1000 ML
20.5.4 1000 ML-2000 ML
20.5.5 2000 ML AND MORE
20.6 OTHERS
21 GLOBAL LARGE VOLUME PARENTERAL MARKET, BY END USER
21.1 OVERVIEW
21.2 HOSPITALS
21.2.1 PUBLIC
21.2.2 PRIVATE
21.3 SPECIALTY CLINICS
21.4 AMBULATORY CENTERS
21.5 OTHERS
22 EUROPE LARGE VOLUME PARENTERAL MARKET, BY DISTRIBUTION CHANNEL
22.1 OVERVIEW
22.2 DIRECT TENDER
22.3 RETAIL SALES
22.3.1 HOSPITAL PHARMACY
22.3.2 RETAIL PHARMCY
22.3.3 OTHERS
22.4 OTHERS
23 GLOBAL LARGE VOLUME PARENTERAL MARKET, SWOT AND DBMR ANALYSIS
24 GLOBAL LARGE VOLUME PARENTERAL MARKET, COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: GLOBAL
24.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.3 COMPANY SHARE ANALYSIS: EUROPE
24.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
24.5 MERGERS & ACQUISITIONS
24.6 NEW PRODUCT DEVELOPMENT & APPROVALS
24.7 EXPANSIONS
24.8 REGULATORY CHANGES
24.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL LARGE VOLUME PARENTERAL MARKET, BY REGION
GLOBAL LARGE VOLUME PARENTERAL MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
25.1 NORTH AMERICA
25.1.1 U.S.
25.1.2 CANADA
25.1.3 MEXICO
25.2 EUROPE
25.2.1 GERMANY
25.2.2 U.K.
25.2.3 ITALY
25.2.4 FRANCE
25.2.5 SPAIN
25.2.6 RUSSIA
25.2.7 SWITZERLAND
25.2.8 TURKEY
25.2.9 BELGIUM
25.2.10 NETHERLANDS
25.2.11 DENMARK
25.2.12 SWEDEN
25.2.13 POLAND
25.2.14 NORWAY
25.2.15 FINLAND
25.2.16 REST OF EUROPE
25.3 ASIA-PACIFIC
25.3.1 JAPAN
25.3.2 CHINA
25.3.3 SOUTH KOREA
25.3.4 INDIA
25.3.5 SINGAPORE
25.3.6 THAILAND
25.3.7 INDONESIA
25.3.8 MALAYSIA
25.3.9 PHILIPPINES
25.3.10 AUSTRALIA
25.3.11 NEW ZEALAND
25.3.12 VIETNAM
25.3.13 TAIWAN
25.3.14 REST OF ASIA-PACIFIC
25.4 SOUTH AMERICA
25.4.1 BRAZIL
25.4.2 ARGENTINA
25.4.3 REST OF SOUTH AMERICA
25.5 MIDDLE EAST AND AFRICA
25.5.1 SOUTH AFRICA
25.5.2 EGYPT
25.5.3 BAHRAIN
25.5.4 UNITED ARAB EMIRATES
25.5.5 KUWAIT
25.5.6 OMAN
25.5.7 QATAR
25.5.8 SAUDI ARABIA
25.5.9 REST OF MEA
25.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
26 GLOBAL LARGE VOLUME PARENTERAL MARKET, COMPANY PROFILE
26.1 BML PARENTERAL DRUGS
26.1.1 COMPANY OVERVIEW
26.1.2 REVENUE ANALYSIS
26.1.3 GEOGRAPHIC PRESENCE
26.1.4 PRODUCT PORTFOLIO
26.1.5 RECENT DEVELOPMENTS
26.2 RUSOMA LABORATORIES PRIVATE LIMITED
26.2.1 COMPANY OVERVIEW
26.2.2 REVENUE ANALYSIS
26.2.3 GEOGRAPHIC PRESENCE
26.2.4 PRODUCT PORTFOLIO
26.2.5 RECENT DEVELOPMENTS
26.3 B. BRAUN SE
26.3.1 COMPANY OVERVIEW
26.3.2 REVENUE ANALYSIS
26.3.3 GEOGRAPHIC PRESENCE
26.3.4 PRODUCT PORTFOLIO
26.3.5 RECENT DEVELOPMENTS
26.4 HIGGS HEALTHCARE
26.4.1 COMPANY OVERVIEW
26.4.2 REVENUE ANALYSIS
26.4.3 GEOGRAPHIC PRESENCE
26.4.4 PRODUCT PORTFOLIO
26.4.5 RECENT DEVELOPMENTS
26.5 TAJ PHARMA INDIA
26.5.1 COMPANY OVERVIEW
26.5.2 REVENUE ANALYSIS
26.5.3 GEOGRAPHIC PRESENCE
26.5.4 PRODUCT PORTFOLIO
26.5.5 RECENT DEVELOPMENTS
26.6 SICHUAN KELUN PHARMACEUTICAL CO., LTD.
26.6.1 COMPANY OVERVIEW
26.6.2 REVENUE ANALYSIS
26.6.3 GEOGRAPHIC PRESENCE
26.6.4 PRODUCT PORTFOLIO
26.6.5 RECENT DEVELOPMENTS
26.7 WEILER ENGINEERING, INC.
26.7.1 COMPANY OVERVIEW
26.7.2 REVENUE ANALYSIS
26.7.3 GEOGRAPHIC PRESENCE
26.7.4 PRODUCT PORTFOLIO
26.7.5 RECENT DEVELOPMENTS
26.8 FLAGSHIP
26.8.1 COMPANY OVERVIEW
26.8.2 REVENUE ANALYSIS
26.8.3 GEOGRAPHIC PRESENCE
26.8.4 PRODUCT PORTFOLIO
26.8.5 RECENT DEVELOPMENTS
26.9 ALBERT DAVID LTD.
26.9.1 COMPANY OVERVIEW
26.9.2 REVENUE ANALYSIS
26.9.3 GEOGRAPHIC PRESENCE
26.9.4 PRODUCT PORTFOLIO
26.9.5 RECENT DEVELOPMENTS
26.1 GRIFOLS S.A.
26.10.1 COMPANY OVERVIEW
26.10.2 REVENUE ANALYSIS
26.10.3 GEOGRAPHIC PRESENCE
26.10.4 PRODUCT PORTFOLIO
26.10.5 RECENT DEVELOPMENTS
26.11 HEBEI TIANCHENG PHARMACEUTICAL CO., LTD.
26.11.1 COMPANY OVERVIEW
26.11.2 REVENUE ANALYSIS
26.11.3 GEOGRAPHIC PRESENCE
26.11.4 PRODUCT PORTFOLIO
26.11.5 RECENT DEVELOPMENTS
26.12 GUIZHOU TIANDI PHARMACEUTICAL CO., LTD.
26.12.1 COMPANY OVERVIEW
26.12.2 REVENUE ANALYSIS
26.12.3 GEOGRAPHIC PRESENCE
26.12.4 PRODUCT PORTFOLIO
26.12.5 RECENT DEVELOPMENTS
26.13 ALTHEA
26.13.1 COMPANY OVERVIEW
26.13.2 REVENUE ANALYSIS
26.13.3 GEOGRAPHIC PRESENCE
26.13.4 PRODUCT PORTFOLIO
26.13.5 RECENT DEVELOPMENTS
26.14 PFIZER
26.14.1 COMPANY OVERVIEW
26.14.2 REVENUE ANALYSIS
26.14.3 GEOGRAPHIC PRESENCE
26.14.4 PRODUCT PORTFOLIO
26.14.5 RECENT DEVELOPMENTS
27 RELATED REPORTS
28 CONCLUSION
29 QUESTIONNAIRE
30 ABOUT DATA BRIDGE MARKET RESEARCH
